Table 3.

Univariate and multivariate Cox proportional-hazards regression analysis for progression-free survival. Abbreviations: PFS: Progression-free survival; HR: Hazard Ratio; CI: Confidence Interval; p: p-value; CTCs: Circulating tumour cells; miR: miRNA; B: Baseline; 12w: 12 weeks; 24w: 24weeks; *p < 0.05.

			Univariate analysis			Multivariate analysis
Characteristics		Median PFS (months)	HR	95% CI	p	HR	95% CI	p
All patients		11.5
Gender	Female	11	1.17	0.55–2.47	0.688	1.62	0.60–4.33	0.339
	Male	14
Age (years)	>55	13.5	0.75	0.36–1.56	0.436	0.49	0.16–1.46	0.198
	<55	10
Primary tumour location	Colon	14	0.34	0.16–0.74	0.006*	0.47	0.18–1.25	0.131
	Rectum	10
Metastasis location	Liver	13			0.509
	Lung	12	0.94	0.43–2.09	0.885
	Other	7	1.73	0.64–4.68	0.281
Metachronous metastasis	Yes	12	1.67	0.63–4.42	0.301
	No	11.5
Metastasis surgery	Yes	14	0.82	0.36–1.85	0.630
	No	11.5
K-RAS status	Mutated	11.5	0.89	0.43–1.81	0.743
	Wild-Type	13.5
CEA (B)	High	11	1.33	0.58–3.06	0.509
	Standard	13
Ca 19.9 (B)	High	14	0.66	0.33–1.31	0.235
	Standard	10
CEA (12w)	High	11	1.46	0.69–3.09	0.324
	Standard	14
Ca 19.9 (12w)	High	13	0.66	0.31–1.38	0.267
	Standard	13
CEA (24w)	High	11	1.48	0.71–3.09	0.302
	Standard	14
Ca 19.9 (24w)	High	14	0.65	0.30–1.41	0.279
	Standard	13
Response (12w)	Favourable	12.5	0.61	0.30–1.25	0.181
	Non-favourable	9.5
Response (24w)	Favourable	14	0.67	0.33–1.36	0.263
	Non-favourable	10
Number of CTCs (B)			1.15	1.02–1.31	0.029*
Number of CTCs (12w)			1.02	0.98–1.05	0.357
Number of CTCs (24w)			0.98	0.75–1.28	0.896
miR-92a (12w)	High	12	2.45	0.83–7.23	0.104	2.36	0.76–7.32	0.138
	Low	14